Trial Profile
IPX233-B14-02: Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs IPX 233 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors IMPAX Laboratories
- 22 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to Australian New Zealand Clinical Trials Registry
- 24 Jun 2014 New trial record